Alpha Cognition Inc
ACOG
Rank in Stocks
#20419
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Share Price
$8.13
Last synced: 2026-10-16
Market Cap
$126.27M
Change (1 day)
-3.79%
Change (1 year)
61.63%
Country
US
Trade Alpha Cognition Inc (ACOG)
Category
Healthcare
EPS for Alpha Cognition Inc (ACOG)
EPS as of June 2026 TTM: $-0.40
According to Alpha Cognition Inc latest financial reports and stock price the company's current EPS (TTM) is $-0.40. At the end of 2022 the company had a EPS of $-0.18 a decrease compared to its 2021 EPS that were of $-0.37.
EPS history for Alpha Cognition Inc from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.40 | 166.67% |
| 2023 | $-0.15 | -16.67% |
| 2022 | $-0.18 | -51.35% |
| 2021 | $-0.37 | -61.46% |
| 2020 | $-0.96 | 357.14% |
| 2019 | $-0.21 | 672.06% |
| 2018 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -4,430.00% |
US
|
|
| $-7.98 | 1,895.00% |
US
|
|
| $-5.29 | 1,222.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,035.00% |
NL
|
